Michelle L Kramer

US Patent:

20070232624, Oct 4, 2007

Filed:

Sep 22, 2006

Appl. No.:

11/534632

Inventors:

Joseph M. Palumbo - Saint Davids CA, US
Marie-Henriette Eerdekens - Dilsen-Stokkern, BE
Michelle Kramer - San Diego CA, US

International Classification:

A61K 31/505

US Classification:

5142594

Abstract:

The present invention provides a pharmaceutical composition, and provides for the use thereof for the treatment of excessive daytime sleepiness and/or a sleep disturbance in a psychiatric patient in need thereof. The pharmaceutical composition comprises a therapeutically effective amount of paliperidone, its pharmaceutically acceptable acid addition salts, enantiomeric forms, and esters thereof, together with a pharmaceutical carrier, and provides a relatively low plasma concentration variation of paliperidone to the psychiatric patient in need of treatment. The present invention also provides for the use of a pharmaceutical composition as defined above, in the preparation of a medicament for the treatment of excessive daytime sleepiness and/or a sleep disturbance in a psychiatric patient in need thereof.

US Patent:

20090227605, Sep 10, 2009

Filed:

Jan 7, 2009

Appl. No.:

12/349980

Inventors:

Michelle Kramer - New Hope PA, US
Peter Briscoe - Newtown PA, US
Sandra Boom - Rucphen, NL
An Vermeulen - Beerse, BE

International Classification:

A61K 31/519
A61P 25/18

US Classification:

51425941

Abstract:

Disclosed are dosage forms and methods comprising benzisoxazole derivatives. More particularly, disclosed are dosage forms, methods, and new uses of benzisoxazole derivatives that provide enhanced efficacy when used in the treatment of schizophrenia and/or bipolar mania.

US Patent:

20060189635, Aug 24, 2006

Filed:

Oct 27, 2005

Appl. No.:

11/262113

Inventors:

Michelle Kramer - New Hope PA, US
Peter Briscoe - Newtown PA, US
Sandra Boom - Rucphen, NL
An Vermeulen - Beerse, BE

International Classification:

A61K 31/519

US Classification:

514259410

Abstract:

Disclosed are dosage forms and methods comprising benzisoxazole derivatives. More particularly, disclosed are dosage forms, methods, and new uses of benzisoxazole derivatives that provide enhanced efficacy when used in the treatment of schizophrenia and/or bipolar mania.